- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Advanced ER , HER2-Negative Breast Cancer
Total 2039 results
-
Peregrine PharmaceuticalsWithdrawnBreast Cancer | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast Cancer | Triple-Negative Breast Neoplasm | ER-Negative PR-Negative HER2-Negative Breast Neoplasms | ER-Negative PR-Negative HER2-Negative Breast Cancer
-
Stemline Therapeutics, Inc.CompletedAdvanced ER+, HER2-Negative Breast CancerUnited States
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom
-
MedSIRStemline Therapeutics, Inc.Not yet recruitingAdvanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
-
Olema Pharmaceuticals, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast CancerUnited States, Korea, Republic of, Australia, Hong Kong, Taiwan, Malaysia, Thailand, Argentina, Belgium, Portugal
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); Syndax PharmaceuticalsTerminatedBreast Cancer | Invasive Breast Cancer | ER-Negative PR-Negative HER2-Negative Breast CancerUnited States
-
Jules Bordet InstituteHoffmann-La Roche; Breast International Group; Institut Curie; International Drug...SuspendedHER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast CancerKorea, Republic of, France, Israel, Belgium, Switzerland, Australia
-
OncoSec Medical IncorporatedCompletedER-Negative PR-Negative HER2-Negative Breast CancerUnited States
-
Royal Marsden NHS Foundation TrustPfizer; Breast Cancer NowRecruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Recurrent Breast Cancer | ER+ Breast CancerUnited Kingdom
-
Massachusetts General HospitalGilead SciencesRecruitingTriple Negative Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast CancerUnited States
-
University Hospital, AkershusVestre Viken Hospital Trust; NovartisRecruitingBreast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast CancerNorway
-
Abramson Cancer Center at Penn MedicineRecruitingBreast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | ER Positive Breast CancerUnited States
-
Merrimack PharmaceuticalsSanofiCompletedER Positive, Her2 Negative Breast Cancer Patients | Triple Negative Breast Cancer PatientsUnited States
-
Royal Marsden NHS Foundation TrustPfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave... and other collaboratorsRecruitingHER2-negative Breast Cancer | ER+ Breast CancerUnited Kingdom, France
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
Organisation for Oncology and Translational ResearchUnknownLetrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal WomenER Positive, HER2 Negative Breast CancerChina
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
The Methodist Hospital Research InstituteEli Lilly and CompanyRecruitingHER2-negative Breast Cancer | ER-Positive Breast CancerUnited States
-
Stanford UniversityUnited States Department of DefenseRecruitingBreast Cancer | HER2-negative Breast Cancer | ER Positive Breast CancerUnited States
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerUnited States, Spain, United Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.Terminated
-
AstraZenecaActive, not recruitingER+ HER2- Advanced Breast CancerJapan
-
AstraZenecaCompletedER+ HER2- Advanced Breast CancerUnited States, United Kingdom, Korea, Republic of
-
Sarah Sammons, MDDaiichi SankyoRecruitingBreast Cancer | Breast Cancer Female | Metastatic Triple-Negative Breast Carcinoma | HER2-negative Breast Cancer | HER2 Negative Breast Carcinoma | ER-negative Breast Cancer | ER Positive Breast CancerUnited States
-
University of MiamiRecruitingBreast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
Shanghai Hengrui Pharmaceutical Co., Ltd.RecruitingER-Positive, HER2-Negative Breast CancerChina
-
AstraZenecaQuotient SciencesCompletedER-positive, HER2-negative Breast CancerUnited Kingdom
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
AstraZenecaRecruitingER-Positive HER2-Negative Breast CancerUnited States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedER+ / HER2- Advanced Breast CancerChina
-
UNICANCERWithdrawnER-positive Her2-negative Early Breast Cancer
-
KU LeuvenNovartisUnknownER Positive, HER2 Negative Breast Cancer NeoplasmsBelgium
-
Fondazione Sandro PitiglianiClinical Research Technology S.r.l.RecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast CancerItaly
-
Imperial College LondonMedical Research Council; ECMCRecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast CancerUnited Kingdom
-
Shenzhen Yangli Pharmaceutical Technology Co., LtdRecruitingMetastatic Breast Cancer | ER+, HER2- Advanced Breast CancerChina
-
Jennifer Lee Caswell-JinNational Cancer Institute (NCI); QED Therapeutics, Inc.TerminatedBreast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
European Organisation for Research and Treatment...Breast International Group; Menarini GroupRecruitingStage IIB Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Stage III Breast CancerBelgium, Italy, Ireland, France, Germany
-
University of Wisconsin, MadisonContext Therapeutics Inc.TerminatedMetastatic Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
Melinda TelliPfizer; BioMarin PharmaceuticalCompletedAdvanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast CancerUnited States
-
Fudan UniversityRecruitingBreast Cancer | Breast Neoplasm | Breast Tumors | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer | Triple-Negative Breast Cancer (TNBC)China
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...United States
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Synta Pharmaceuticals Corp.CompletedBreast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal TreatmentSpain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
-
VelosBio Inc.CompletedGastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditionsUnited States, Canada